CapsoVision Launches $100M ATM Program Amid Widening Losses
CV sits 92% above its 52-week low of $3.434.
Summary
CapsoVision announced a $100M ATM offering with Cantor Fitzgerald and reported Q2 results with a $7.5M net loss and $9.1M cash balance.
Key Events · Financing and Capital Events · CV
-
$100M ATM Program Established
CapsoVision entered a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald to sell up to $100 million of common stock from time to time at market prices.
-
Q2 Loss Widens
Net loss for Q2 2026 was $7.5 million, up from $4.6 million a year earlier, driven by higher R&D and G&A expenses.
-
Cash Position Tightens
Cash and equivalents fell to $9.1 million as of June 30, 2026, from $10.1 million at year-end 2025, with operating cash burn of $14.5 million in the first half.
-
Regulatory Milestones Ahead
Company expects FDA clearance of AI Highlights by end of Q3 2026 and plans a 510(k) submission for CapsoCam Colon in Q4 2026.
Analysis · CV · Industrial Applications And Services
CapsoVision entered a $100 million at-the-market equity offering agreement with Cantor Fitzgerald, giving the company a flexible financing tool but creating potential dilution for existing shareholders. The company also reported Q2 results showing a net loss of $7.5 million and cash of $9.1 million, underscoring the need for additional capital. The ATM program, combined with the company's going-concern warning from its last 10-Q, suggests management is proactively securing runway, though the overhang could pressure the stock.
At the time of this filing, CV was trading at $6.60 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $339.3M. The 52-week trading range was $3.43 to $15.37. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.